Table 4.
Retrospective studies for early stage cervical cancer with intermediate-risk
| Authur | Year | No. patients | Regimen [courses] | No (%) recurrences | DFS | OS |
| DFS, disease free survival; OS, overall survival; BOMP, bleomycin/vincristine/mitomycin/cisplatin; TP, paclitaxel/cisplatin; PF, cisplatin/5-fluorouracil; EP, etoposide/cisplatin; BVP, bleomycin/vincristine/cisplatin; BP, bleomycin/cisplatin; CP, irinotecan/5-fluorouracil; PFM, cisplatin/mitomycin/5-fluorouracil. | ||||||
| Takeshima et al. (18) | 2006 | 30 | BOMP [3] | 1 (3.3%) | 5-y 93.3% | Not described |
| Hosaka et al. (19) | 2008 | 27 | BOMP [3] | 1 (3.7%) | 3-y 96.3% | Not described |
| Lee et al. (29) | 2008 | 38 | PF or TP [3] | 3 (7.9%) | 5-y about 88% | incomplete |
| Angioli et al. (21) | 2012 | 61 | TP [3] | 6 (9.8%) | 5-y 81% | 5-y 88% |
| Hosaka et al. (20) | 2012 | 32 | TP [3-6] | 7 (21.9%) | 3-y 78.1% | 3-y 93.8% |
| Lee et al. (30) | 2013 | 78 | PF or EP [1-6] | Not described | Not described | 5-y 94.9% |
| Li et al. (31) | 2013 | 1010 | TP, BVP, PF, BP, CP or PFM [2-6] | 167 (16.5%) | 5-y 84.5% | 5-y 86.5% |